GEN Exclusives

More »

GEN News Highlights

More »
Jul 30, 2007

Eden Biodesign and University of Birmingham Ink Therapeutic Deal


  • Eden Biodesign has been selected by the University of Birmingham to develop and produce vOX2:Fc, a therapeutic candidate for the treatment of autoimmune diseases such as multiple sclerosis and rheumatoid arthritis. The university’s David Blackbourn, Ph.D., has been investigating the molecule.

    “Working with Eden Biodesign will allow us to advance our understanding of the therapeutic potential of this drug candidate; clinical applications for this novel therapy could range from autoimmune diseases such as rheumatoid arthritis to asthma and allergy,” notes Dr. Blackbourn.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Should “Special K” Get Special Treatment?

In the near term, what is the best way to use ketamine in treating depression?